Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus chidamide maintenance after concurrent chemoradiotherapy for unresectable stage III NSCLC
ChiCTR2000039464Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and tucidinostat in non-small cell lung cancer (NSCLC), sponsored by Chinese PLA General Hospital. Primary endpoint: Safety. Started Nov 2020; status: recruiting.
02
Drugs
tislelizumabtucidinostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000039464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039464.